|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:administeredBy
|
oral tablet
|
|
gptkbp:approved_for_medical_use
|
1989
|
|
gptkbp:ATCCode
|
P01BC02
|
|
gptkbp:CASNumber
|
53230-10-7
|
|
gptkbp:category
|
antimalarial agent
quinoline methanol
|
|
gptkbp:chemicalFormula
|
C17H16F6N2O
|
|
gptkbp:contraindication
|
history of seizures
history of psychiatric disorders
|
|
gptkbp:developedBy
|
1970s
|
|
gptkbp:discoveredBy
|
gptkb:United_States_Army
|
|
gptkbp:eliminationHalfLife
|
2–4 weeks
|
|
gptkbp:excretion
|
urine
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
mefloquine
|
|
gptkbp:interactsWith
|
anticonvulsants
other antimalarial drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits heme polymerase in Plasmodium
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
378.32 g/mol
|
|
gptkbp:patent
|
1970s
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:riskFactor
|
QT prolongation
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
neuropsychiatric effects
vivid dreams
|
|
gptkbp:synonym
|
gptkb:Mephaquin
gptkb:Lariam
|
|
gptkbp:usedFor
|
malaria treatment
malaria prevention
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Plasmodium_falciparum
|
|
gptkbp:bfsLayer
|
5
|